Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 7 months ago

Anticoagulation

Prevention & Chronic Conditions
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
What’s New in the European ACS Guidelines and How Will My Practice Change?
Author(s): Robert F Storey , Dominick J Angiolillo , Christopher P Cannon , et al Added: 2 years ago
Led byProf Robert Storey (University of Sheffield, Sheffield, UK), this on-demand version of the live broadcast delves into the2023 ACS guideline updates that were recently presented at the European Society of Cardiology (ESC) annual meeting in Amsterdam. Join the conversation withDr Dominick Angiolillo (University of Florida, Gainesville, US), Dr Christopher Cannon (Brigham and Women's… View more

Anticoagulation

Guidelines & Statements
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 9 months ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 7 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
Nothing to REFINE Yet
Author(s): Gheorghe-Andrei Dan Added: 1 month ago

Guidelines & Statements

Heart Failure